Skip to main
CLSD
CLSD logo

Clearside Biomedical (CLSD) Stock Forecast & Price Target

Clearside Biomedical (CLSD) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Clearside Biomedical has made significant progress with its CLS-AX development, showing promising results in the Phase 1/2a OASIS trial and the Phase 2b ODYSSEY trial, with a Phase 3 program anticipated to commence in 2025. The company's innovative SCS injection platform offers a flexible dosing regimen of just 2-4 injections per year, which could enhance treatment compliance and effectiveness compared to current therapies requiring more frequent administration. Additionally, the potential for generating additional revenue through partnerships for the delivery of proprietary drug candidates to the suprachoroidal space supports a positive outlook for Clearside's financial growth.

Bears say

Clearside Biomedical faces substantial risks that could hinder the success of its clinical candidates, particularly CLS-AX, which may experience efficacy or safety issues during trials, leading to significant setbacks. Additionally, the prospects of CLS-AX securing regulatory approval and achieving commercial viability are uncertain and could be adversely affected by market dynamics, competition, and penetration rates. Furthermore, the potential for dilution presents an additional financial risk that could impact shareholder value, contributing to an overall negative outlook on the company's stock.

Clearside Biomedical (CLSD) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearside Biomedical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearside Biomedical (CLSD) Forecast

Analysts have given Clearside Biomedical (CLSD) a Buy based on their latest research and market trends.

According to 12 analysts, Clearside Biomedical (CLSD) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearside Biomedical (CLSD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.